4.7 Article

Delivery of a chemotherapeutic drug using novel hollow carbon spheres for esophageal cancer treatment

Journal

INTERNATIONAL JOURNAL OF NANOMEDICINE
Volume 12, Issue -, Pages 6759-6769

Publisher

DOVE MEDICAL PRESS LTD
DOI: 10.2147/IJN.S142916

Keywords

hollow carbon spheres; drug delivery; doxorubicin; esophagus carcinoma

Funding

  1. National Natural Science Foundation of China [81572977, 81772585, 81572421]
  2. Natural Science Foundation of Jiangsu Province [BK20150421]
  3. International S&T Cooperation Projects of Huai'an [HAC2015015]
  4. Huai'an Key Laboratory of Esophageal Cancer Biobank Project [HAP201606]

Ask authors/readers for more resources

Low toxicity and high efficacy are the key factors influencing the real-world clinical applications of nanomaterial-assisted drug delivery. In this study, novel hollow carbon spheres (HCSs) with narrow size distribution were developed. In addition to demonstrating their ease of synthesis for large-scale production, we also demonstrated in vitro that the HCSs possessed high drug-loading capacity, lower cell toxicity, and optimal drug release profile at low pH, similar to the pH in the tumor microenvironment. The HCSs also displayed excellent immunocompatibility and could rapidly distribute themselves in the cytoplasm to escape lysosomal clearance. More importantly, the HCSs could efficiently deliver doxorubicin (a representative chemotherapeutic drug) to tumor sites, which resulted in significant inhibition of tumor growth in an esophageal xenograft cancer model. This also prolonged the circulation time and altered the biodistribution of the drug. In conclusion, this study revealed a novel drug delivery system for targeted tumor therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Genetics & Heredity

Genetic and phenotypic difference in CD8(+) T cell exhaustion between chronic hepatitis B infection and hepatocellular carcinoma

Xiaochen Wang, Qifeng He, Haiyuan Shen, Xiao-Jie Lu, Beicheng Sun

JOURNAL OF MEDICAL GENETICS (2019)

Review Cell Biology

Comprehensive treatments for hepatocellular carcinoma with portal vein tumor thrombosis

Jin-Cheng Wang, An-Liang Xia, Yong Xu, Xiao-Jie Lu

JOURNAL OF CELLULAR PHYSIOLOGY (2019)

Article Cell Biology

The landscape of DNA methylation in hepatocellular carcinoma

Yong-Fa Zheng, Xiaojie Lu, Xiao-Yu Zhang, Bu-Gao Guan

JOURNAL OF CELLULAR PHYSIOLOGY (2019)

Review Cell Biology

Gut microbiome and cancer immunotherapy

Jin-Yu Sun, Tai-Lang Yin, Jianhua Zhou, Jiang Xu, Xiao-Jie Lu

JOURNAL OF CELLULAR PHYSIOLOGY (2020)

Article Cell Biology

Hsa_circ_0070963 inhibits liver fibrosis via regulation of miR-223-3p and LEMD3

Dong Ji, Guo-Feng Chen, Jin-Cheng Wang, Si-Han Ji, Xue-Wen Wu, Xiao-Jie Lu, Jin-Lian Chen, Jing-Tao Li

AGING-US (2020)

Editorial Material Oncology

Featuring the special issue guest editor

Xiao-Jie Lu

CANCER LETTERS (2020)

Editorial Material Oncology

Cancer immunotherapy: Current applications and challenges

Jin-Yu Sun, Xiao-Jie Lu

CANCER LETTERS (2020)

Review Oncology

Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives

Jin-Yu Sun, Dengke Zhang, Songquan Wu, Min Xu, Xiao Zhou, Xiao-Jie Lu, Jiansong Ji

BIOMARKER RESEARCH (2020)

Article Oncology

FibroBox: a novel noninvasive tool for predicting significant liver fibrosis and cirrhosis in HBV infected patients

Xiao-Jie Lu, Xiao-Jun Yang, Jing-Yu Sun, Xin Zhang, Zhao-Xin Yuan, Xiu-Hui Li

BIOMARKER RESEARCH (2020)

Editorial Material Genetics & Heredity

The mechanisms and functions of circular RNAs in human diseases

Xiaoling Weng, Xiao-Jie Lu

Article Cell Biology

Circular RNA Circ0021205 Promotes Cholangiocarcinoma Progression Through MiR-204-5p/RAB22A Axis

Jianfei Tu, Weiqian Chen, Liyun Zheng, Shiji Fang, Dengke Zhang, Chunli Kong, Yang Yang, Rongfang Qiu, Zhongwei Zhao, Chenying Lu, Xiaojie Lu, Jiansong Ji

Summary: The study revealed that circ_0021205 was up-regulated in CCA and positively correlated with tumor size and TNM stage. It promoted the proliferation, migration, and invasion of CCA cells by sponging miR-204-5p and regulating the expression of RAB22A, serving as a potential diagnostic biomarker or therapeutic target for CCA.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

Review Immunology

Placental Immune Tolerance and Organ Transplantation: Underlying Interconnections and Clinical Implications

Jin-Yu Sun, Rui Wu, Jiang Xu, Hui-Ying Xue, Xiao-Jie Lu, Jiansong Ji

Summary: The immune system plays a crucial role in recognizing and attacking non-self antigens, leading to immunity against infection. However, it also causes immune rejection during organ transplantation. Understanding the mechanisms of maternal-fetal immune tolerance can potentially improve transplantation outcomes by balancing immune tolerance and infection defense. Studies exploring the interconnection between immune tolerance in pregnancy and organ transplantation highlight the impact of pregnancy alloimmunization on transplant success.

FRONTIERS IN IMMUNOLOGY (2021)

Editorial Material Cell Biology

Circular RNA and human diseases: Basic research and translational implications

Xiaoling Weng, Xiao-Jie Lu

CELLULAR SIGNALLING (2021)

Article Cell Biology

Downregulation of TPX2 impairs the antitumor activity of CD8+T cells in hepatocellular carcinoma

Xiaochen Wang, Jianchu Wang, Haiyuan Shen, Zongjiang Luo, Xiaojie Lu

Summary: This study found that TPX2 regulates the antitumor effect of CD8 + T cells in hepatocellular carcinoma (HCC) by modulating CXCR5. Overexpression of TPX2 enhances the anticancer function of CD8 + T cells and shows synergistic effects with anti-PD-1 therapy.

CELL DEATH & DISEASE (2022)

Review Oncology

Management of patients with intermediate stage hepatocellular carcinoma

David Prince, Ken Liu, Weiqi Xu, Minjiang Chen, Jin-Yu Sun, Xiao-Jie Lu, Jiansong Ji

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)

No Data Available